Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy

Che Hsin Lee, Chao-Liang Wu, Yun Sheng Tai, Ai-Li Shiau

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Some anaerobic and facultative anaerobic bacteria have been employed as anticancer agents. Previously, we have demonstrated tumor-targeting and antitumor activities of attenuated Salmonella choleraesuis carrying antiangiogenic genes. Here we exploited S. choleraesuis as a single-agent therapy and as part of a combination therapy with low-dose cisplatin for syngeneic murine lung tumor and hepatoma. Systemically injected S. choleraesuis preferentially accumulated within tumors for at least 4 weeks and the bacteria accumulated preferentially in not only subcutaneous but also orthotopic tumors over livers and spleens at ratios ranging from 1000:1 to 100,000:1. S. choleraesuis was capable of delaying tumor growth and enhancing survival in both subcutaneous tumor and experimental metastasis models. More strikingly, the combination of S. choleraesuis plus cisplatin acted additively to retard tumor growth and extensively prolong the survival time of the mice bearing hepatomas or lung tumors. Such combination treatment also increased infiltrating neutrophils and CD8+ T cells, as well as apoptotic cells, in the tumors, compared with S. choleraesuis or cisplatin treatment alone. These findings suggest that S. choleraesuis in combination with cisplatin, which exerts oncolytic effects and enhances antitumor immune responses, represents a promising strategy for the treatment of primary and metastatic tumors.

Original languageEnglish
Pages (from-to)707-716
Number of pages10
JournalMolecular Therapy
Volume11
Issue number5
DOIs
Publication statusPublished - 2005 May 1

Fingerprint

Salmonella
Cisplatin
Neoplasms
Therapeutics
Hepatocellular Carcinoma
Lung
Anaerobic Bacteria
Growth
Antineoplastic Agents
Neutrophils
Theoretical Models
Spleen
Neoplasm Metastasis
Bacteria
T-Lymphocytes
Liver

All Science Journal Classification (ASJC) codes

  • Molecular Biology

Cite this

@article{600d08c80ee247e3b8e3cd7d81180b55,
title = "Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy",
abstract = "Some anaerobic and facultative anaerobic bacteria have been employed as anticancer agents. Previously, we have demonstrated tumor-targeting and antitumor activities of attenuated Salmonella choleraesuis carrying antiangiogenic genes. Here we exploited S. choleraesuis as a single-agent therapy and as part of a combination therapy with low-dose cisplatin for syngeneic murine lung tumor and hepatoma. Systemically injected S. choleraesuis preferentially accumulated within tumors for at least 4 weeks and the bacteria accumulated preferentially in not only subcutaneous but also orthotopic tumors over livers and spleens at ratios ranging from 1000:1 to 100,000:1. S. choleraesuis was capable of delaying tumor growth and enhancing survival in both subcutaneous tumor and experimental metastasis models. More strikingly, the combination of S. choleraesuis plus cisplatin acted additively to retard tumor growth and extensively prolong the survival time of the mice bearing hepatomas or lung tumors. Such combination treatment also increased infiltrating neutrophils and CD8+ T cells, as well as apoptotic cells, in the tumors, compared with S. choleraesuis or cisplatin treatment alone. These findings suggest that S. choleraesuis in combination with cisplatin, which exerts oncolytic effects and enhances antitumor immune responses, represents a promising strategy for the treatment of primary and metastatic tumors.",
author = "Lee, {Che Hsin} and Chao-Liang Wu and Tai, {Yun Sheng} and Ai-Li Shiau",
year = "2005",
month = "5",
day = "1",
doi = "10.1016/j.ymthe.2005.01.008",
language = "English",
volume = "11",
pages = "707--716",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. / Lee, Che Hsin; Wu, Chao-Liang; Tai, Yun Sheng; Shiau, Ai-Li.

In: Molecular Therapy, Vol. 11, No. 5, 01.05.2005, p. 707-716.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy

AU - Lee, Che Hsin

AU - Wu, Chao-Liang

AU - Tai, Yun Sheng

AU - Shiau, Ai-Li

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Some anaerobic and facultative anaerobic bacteria have been employed as anticancer agents. Previously, we have demonstrated tumor-targeting and antitumor activities of attenuated Salmonella choleraesuis carrying antiangiogenic genes. Here we exploited S. choleraesuis as a single-agent therapy and as part of a combination therapy with low-dose cisplatin for syngeneic murine lung tumor and hepatoma. Systemically injected S. choleraesuis preferentially accumulated within tumors for at least 4 weeks and the bacteria accumulated preferentially in not only subcutaneous but also orthotopic tumors over livers and spleens at ratios ranging from 1000:1 to 100,000:1. S. choleraesuis was capable of delaying tumor growth and enhancing survival in both subcutaneous tumor and experimental metastasis models. More strikingly, the combination of S. choleraesuis plus cisplatin acted additively to retard tumor growth and extensively prolong the survival time of the mice bearing hepatomas or lung tumors. Such combination treatment also increased infiltrating neutrophils and CD8+ T cells, as well as apoptotic cells, in the tumors, compared with S. choleraesuis or cisplatin treatment alone. These findings suggest that S. choleraesuis in combination with cisplatin, which exerts oncolytic effects and enhances antitumor immune responses, represents a promising strategy for the treatment of primary and metastatic tumors.

AB - Some anaerobic and facultative anaerobic bacteria have been employed as anticancer agents. Previously, we have demonstrated tumor-targeting and antitumor activities of attenuated Salmonella choleraesuis carrying antiangiogenic genes. Here we exploited S. choleraesuis as a single-agent therapy and as part of a combination therapy with low-dose cisplatin for syngeneic murine lung tumor and hepatoma. Systemically injected S. choleraesuis preferentially accumulated within tumors for at least 4 weeks and the bacteria accumulated preferentially in not only subcutaneous but also orthotopic tumors over livers and spleens at ratios ranging from 1000:1 to 100,000:1. S. choleraesuis was capable of delaying tumor growth and enhancing survival in both subcutaneous tumor and experimental metastasis models. More strikingly, the combination of S. choleraesuis plus cisplatin acted additively to retard tumor growth and extensively prolong the survival time of the mice bearing hepatomas or lung tumors. Such combination treatment also increased infiltrating neutrophils and CD8+ T cells, as well as apoptotic cells, in the tumors, compared with S. choleraesuis or cisplatin treatment alone. These findings suggest that S. choleraesuis in combination with cisplatin, which exerts oncolytic effects and enhances antitumor immune responses, represents a promising strategy for the treatment of primary and metastatic tumors.

UR - http://www.scopus.com/inward/record.url?scp=17644426990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644426990&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2005.01.008

DO - 10.1016/j.ymthe.2005.01.008

M3 - Article

VL - 11

SP - 707

EP - 716

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -